http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#Head
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#assertion
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#provenance
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#pubinfo
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#assertion
http://purl.obolibrary.org/obo/DOID_8536
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_8536
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00299
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#association
http://www.w3.org/2000/01/rdf-schema#label
famciclovir a prodrug of penciclovir is a nucleoside analog dna polymerase inhibitor indicated for immunocompetent adult patients 1 1 herpes labialis cold sores treatment of recurrent episodes genital herpes treatment of recurrent episodes suppressive therapy of recurrent episodes herpes zoster shingles hiv infected adult patients 1 2 treatment of recurrent episodes of orolabial or genital herpes limitation of use 1 3 the efficacy and safety of famciclovir have not been established for patients 18 years of age immunocompromised patients other than for the treatment of recurrent episodes of orolabial or genital herpes in hiv infected patients black and african american patients with recurrent genital herpes herpes labialis cold sores genital herpes recurrent episodes suppressive therapy herpes zoster shingles recurrent orolabial or genital herpes famciclovir tablets are indicated for the treatment of recurrent episodes of orolabial or genital herpes in hiv infected adults the efficacy of famciclovir tablets when initiated more than 48 hours after onset of symptoms or lesions has not been established the efficacy and safety of famciclovir tablets have not been established for patients 18 years of age patients with first episode of genital herpes patients with ophthalmic zoster immunocompromised patients other than for the treatment of recurrent orolabial or genital herpes in hiv infected patients black and african american patients with recurrent genital herpes
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00299
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#provenance
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#pubinfo
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#sig
http://purl.org/nanopub/x/hasSignature
HVdu8i+illjVM1vNKw9G1EyBQ/mpjnAxmkl5VCd0v/6/1rEghDeX0iZvLdwiAgdV+ao7LNkcW/iwS4h/R+LPsGE54Ldia0wk9IBX5YmS0lXiJgeRa+MIMlrDbRoyKRRxxWQ1zDOWIrSqsRwdICDqTkgqXlwRrnclmydRRG6IlEk=
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA
http://purl.org/dc/terms/created
2021-06-15T18:34:09.095+02:00
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs